A large number of complementary and herbal medicines, cough and throat lozenges and pastilles are authorised in the course of a year.
The newly authorised medicines, excluding authorisations from the notification procedure, can be found in the Swissmedic Journals from the respective year.
All information about the medicinal products reflects the situation on the respective date of authorisation. The current medicinal product information for authorised medicinal products can be found at
A report providing detailed information about the authorisation of complementary and herbal medicines, including details of the authorisation procedures used and statistical evaluations, is also available as of 2021 under Overview.
Orphan drug status for a herbal medicinal product
The report from the CHM Division provides an overview of the newly authorised complementary and herbal medicinal products in 2024 and illustrates trends in the numbers of medicinal products authorised in each school of therapy.
An application for orphan drug status was approved for the first time in the CHM Division (active substance: dry extract of birch bark) for the treatment of the rare disease “epidermolysis bullosa”.
Important activities of the CHM Division are also reported.
